Innate immunity and the failing heart: The cytokine hypothesis revisited

Circulation Research

Volumn 116, Issue 7, 2015, Pages 1254-1268

  Mann, Douglas L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Heart failure; Inflammation; Innate immunity

Indexed keywords

ALLOPURINOL; BIOLOGICAL MARKER; CYTOKINE; DEXAMETHASONE; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; OMEGA 3 FATTY ACID; OXIPURINOL; PENTOXIFYLLINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PATTERN RECOGNITION RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CYTOKINE RESPONSE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRIPTION REGULATION; ADAPTIVE IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; COMPLICATION; IMMUNOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOMARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOKINES; DEXAMETHASONE; HEART FAILURE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MODELS, CARDIOVASCULAR; MODELS, IMMUNOLOGICAL; PENTOXIFYLLINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84939247051     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.302317     Document Type: Review

References (89)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241. doi: 10.1056/NEJM199007263230405.
2. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL, Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998 97 1382 1391
3. Mann DL, Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002 91 988 998
4. Mann DL, McMurray JJV, Packer M, Targeted anti-cytokine therapy in patients with chronic heart failure: results of the Randomized EtaNcercept Worldwide evALuation (RENEWAL). Circulation 2004; 109: 1594-1602. doi: 10.1161/01.CIR.0000124490.27666.B2.
5. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140. doi: 10.1161/01.CIR.0000077913.60364.D2.
6. Medzhitov R, Origin and physiological roles of inflammation. Nature 2008; 454: 428-435. doi: 10.1038/nature07201.
7. Mann DL, Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003; 65: 81-101. doi: 10.1146/annurev.physiol.65.092101.142249.
8. Tauber AI, The immunological self: a centenary perspective. Perspect Biol Med 1991 35 74 86
9. Mann DL, Mann DL, Felker GM, The role of innate immunity in heart failure. In: Heart Failure: A Companion to Braunwald's Heart Disease 2015 Philadelphia, PA Elsevier/Saunders 109 126
10. Mann DL, Topkara VK, Evans S, Barger PM, Innate immunity in the adult Mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc 2010 121 34 50
11. Mezzaroma E, Toldo S, Farkas D, Seropian IM, Van Tassell BW, Salloum FN, Kannan HR, Menna AC, Voelkel NF, Abbate A, The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 2011; 108: 19725-19730. doi: 10.1073/pnas.1108586108.
12. Nishimura M, Naito S, Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005 28 886 892
13. Frantz S, Kelly RA, Bourcier T, Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol Chem 2001; 276: 5197-5203. doi: 10.1074/jbc.M009160200.
14. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA, Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104: 271-280. doi: 10.1172/JCI6709.
15. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH, Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 2004; 23: 228-235. doi: 10.1016/S1053-2498(03)00106-2.
16. Lech M, Susanti HE, Römmele C, Gröbmayr R, Günthner R, Anders HJ, Quantitative expression of C-type lectin receptors in humans and mice. Int J Mol Sci 2012; 13: 10113-10131. doi: 10.3390/ijms130810113.
17. Takeuchi O, Akira S, Pattern recognition receptors and inflammation. Cell 2010; 140: 805-820. doi: 10.1016/j.cell.2010.01.022.
18. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, Hornung V, Vogel SN, Szomolanyi-Tsuda E, Fitzgerald KA, The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010; 11: 395-402. doi: 10.1038/ni.1864.
19. Geddes K, Magalhães JG, Girardin SE, Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov 2009; 8: 465-479. doi: 10.1038/nrd2783.
20. Kawaguchi M, Takahashi M, Hata T, Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011; 123: 594-604. doi: 10.1161/CIRCULATIONAHA.110.982777.
21. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL, Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996 93 704 711
22. Kalra D, Sivasubramanian N, Mann DL, Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 2002 105 2198 2205
23. Murray DR, Prabhu SD, Chandrasekar B, Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000 101 2338 2341
24. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL, Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996 2 243 249
25. Prabhu SD, Cytokine-induced modulation of cardiac function. Circ Res 2004; 95: 1140-1153. doi: 10.1161/01.RES.0000150734.79804.92.
26. Franco F, Thomas GD, Giroir B, Bryant D, Bullock MC, Chwialkowski MC, Victor RG, Peshock RM, Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1999 99 448 454
27. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA, Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 2001; 98: 2871-2876. doi: 10.1073/pnas.041611398.
28. Mann DL, The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011; 108: 1133-1145. doi: 10.1161/CIRCRESAHA.110.226936.
29. Tzeng HP, Evans S, Gao F, Chambers K, Topkara VK, Sivasubramanian N, Barger PM, Mann DL, Dysferlin mediates the cytoprotective effects of TRAF2 following myocardial ischemia reperfusion injury. J Am Heart Assoc 2014 3 e000662. doi: 10.1161/JAHA.113.000662.
30. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, Mann DL, Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001 104 826 831
31. Zhang W, Chancey AL, Tzeng HP, Zhou Z, Lavine KJ, Gao F, Sivasubramanian N, Barger PM, Mann DL, The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 2011; 124: 2106-2116. doi: 10.1161/CIRCULATIONAHA.111.052399.
32. Hartupee J, Mann DL, Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res 2013; 6: 485-492. doi: 10.1007/s12265-013-9467-y.
33. Latini R, Gullestad L, Masson S, Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail 2012; 14: 992-999. doi: 10.1093/eurjhf/hfs092.
34. Kjekshus J, Apetrei E, Barrios V, CORONA Group Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261. doi: 10.1056/NEJMoa0706201.
35. Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E, Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail 2013 6 862 868
36. Gissi-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 372 1231 1239
37. Gullestad L, Ueland T, Fjeld JG, Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005; 112: 3408-3414. doi: 10.1161/CIRCULATIONAHA.105.564971.
38. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP, OPT-CHF Investigators Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51: 2301-2309. doi: 10.1016/j.jacc.2008.01.068.
39. Parrillo JE, Cunnion RE, Epstein SE, Parker ME, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, Alling D, Wittes JT, Ferrans VJ, Rodriguez ER, Fauci AS, A prospective randomized controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1061-1068. doi: 10.1056/NEJM198910193211601.
40. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P, Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001 103 1083 1088
41. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P, Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351: 1091-1093. doi: 10.1016/S0140-6736(97)09338-0.
42. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, Skudicky D, Sareli P, Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002 90 1118 1122
43. Sliwa K, Woodiwiss A, Kone VN, Candy G, Badenhorst D, Norton G, Zambakides C, Peters F, Essop R, Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 2004; 109: 750-755. doi: 10.1161/01.CIR.0000112568.48837.60.
44. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A, Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007; 13: 1-7. doi: 10.1016/j.cardfail.2006.09.008.
45. Torre-Amione G, Anker SD, Bourge RC, Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008; 371: 228-236. doi: 10.1016/S0140-6736(08)60134-8.
46. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland SS, Aukrust P, Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001 103 220 225
47. McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G, Gass A, Janosko K, Tokarczyk T, Kessler P, Mann DL, Feldman AM, Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001 103 2254 2259
48. Moreira DM, Vieira JL, Gottschall CA, The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). J Card Fail 2009; 15: 828-834. doi: 10.1016/j.cardfail.2009.06.439.
49. Aukrust Gullestad L, Ueland T, Vinge LE, Finsen A, Yndestad A, Aukrust P, Inflammatory cytokines in heart failure: mediators and markers. Cardiology 2012; 122: 23-35. doi: 10.1159/000338166.
50. Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, Skudicky D, Sareli P, Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 2002 90 1118 1122
51. Skudicky D, Sliwa K, Bergemann A, Candy G, Sareli P, Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline. Heart 2000 84 438 439
52. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G, Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993 177 1675 1680
53. Agoston I, Dibbs ZI, Wang F, Muller G, Zeldis JB, Mann DL, Bozkurt B, Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Card Fail 2002 8 306 314
54. Mann DL, Mann DL, Activation of inflammatory mediators in heart failure. In: Heart failure: A Companion to Braunwald's Heart Disease 2011 2nd ed Philadelphia, PA Elsevier/Saunders 163 184
55. Klein B, Brailly H, Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995; 16: 216-220. doi: 10.1016/0167-5699(95)80161-8.
56. Packer M, Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001; 7: 176-182. doi: 10.1054/jcaf.2001.25652.
57. Homeister JW, Lucchesi BR, Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol 1994; 34: 17-40. doi: 10.1146/annurev.pa.34.040194.000313.
58. Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM, Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 138 807 811
59. Wolfe F, Michaud K, Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305-311. doi: 10.1016/j.amjmed.2003.09.039.
60. Nicola PJ, Crowson CS, Maradit-Kremers H, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE, Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006; 54: 60-67. doi: 10.1002/art.21560.
61. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF, Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005 43 480 485
62. Singh JA, Furst DE, Bharat A, 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-639. doi: 10.1002/acr.21641.
63. Abbate A, Salloum FN, Van Tassell BW, Vecile E, Toldo S, Seropian I, Mezzaroma E, Dobrina A, Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One 2011 6 e27923. doi: 10.1371/journal.pone.0027923.
64. Abbate A, Van Tassell BW, Biondi-Zoccai G, Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013; 111: 1394-1400. doi: 10.1016/j.amjcard.2013.01.287.
65. Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A, Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 2014; 113: 321-327. doi: 10.1016/j.amjcard.2013.08.047.
66. Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A, Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One 2012 7 e33438. doi: 10.1371/journal.pone.0033438.
67. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL, Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51: 415-426. doi: 10.1016/j.jacc.2007.10.009.
68. McMurray JJ, Kjekshus J, Gullestad L, CORONA Study Group Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009; 120: 2188-2196. doi: 10.1161/CIRCULATIONAHA.109.849117.
69. Yancy CW, Jessup M, Bozkurt B, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852. doi: 10.1161/CIR.0b013e31829e8807.
70. Anker SD, Doehner W, Rauchhaus M, Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997. doi: 10.1161/01.CIR.0000065637.10517.A0.
71. Ghaemi-Oskouie F, Shi Y, The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011; 13: 160-166. doi: 10.1007/s11926-011-0162-1.
72. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD, Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res 2014; 114: 266-282. doi: 10.1161/CIRCRESAHA.113.301720.
73. Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T, Frantz S, Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation 2012; 125: 1652-1663. doi: 10.1161/CIRCULATIONAHA.111.044164.
74. Epelman S, Lavine KJ, Beaudin AE, Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 2014; 40: 91-104. doi: 10.1016/j.immuni.2013.11.019.
75. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE, The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52: 412-420. doi: 10.1002/art.20855.
76. Crowson CS, Nicola PJ, Kremers HM, O'Fallon WM, Therneau TM, Jacobsen SJ, Roger VL, Ballman KV, Gabriel SE, How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005; 52: 3039-3044. doi: 10.1002/art.21349.
77. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH, Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156: 336-341. doi: 10.1016/j.ahj.2008.02.025.
78. Gong K, Zhang Z, Sun X, Zhang X, Li A, Yan J, Luo Q, Gao Y, Feng Y, The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J 2006; 151: 62-68. doi: 10.1016/j.ahj.2005.02.040.
79. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM, Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101: 890-898. doi: 10.1172/JCI1112.
80. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L, Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999 83 376 382
81. Torre-Amione G, Sestier F, Radovancevic B, Young J, Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004; 44: 1181-1186. doi: 10.1016/j.jacc.2004.06.047.
82. Eriksson U, Ricci R, Hunziker L, Kurrer MO, Oudit GY, Watts TH, Sonderegger I, Bachmaier K, Kopf M, Penninger JM, Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 2003; 9: 1484-1490. doi: 10.1038/nm960.
83. Kaya Z, Leib C, Katus HA, Autoantibodies in heart failure and cardiac dysfunction. Circ Res 2012; 110: 145-158. doi: 10.1161/CIRCRESAHA.111.243360.
84. Rose NR, Infection, mimics, and autoimmune disease. J Clin Invest 2001; 107: 943-944. doi: 10.1172/JCI12673.
85. Mann DL, Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: has the time come for randomized clinical trials? J Am Coll Cardiol 2001 38 184 186
86. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ, Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419-1429. doi: 10.1172/JCI20149.
87. Münch G, Boivin-Jahns V, Holthoff HP, Adler K, Lappo M, Truöl S, Degen H, Steiger N, Lohse MJ, Jahns R, Ungerer M, Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-β1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail 2012; 14: 1230-1239. doi: 10.1093/eurjhf/hfs118.
88. Liu Y, Yin H, Zhao M, Lu Q, TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol 2014; 47: 136-147. doi: 10.1007/s12016-013-8402-y.
89. Fleming TR, DeMets DL, Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996 125 605 613